NCT03393520: An ongoing trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03393520 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 13, 2017 |
| Completion date | Nov. 17, 2023 |
| Required reporting date | Nov. 17, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |